Peroxisome proliferator-activated receptor γ ligand pioglitazone alters neointimal composition in a balloon-denuded and radiated hypercholesterolemic rabbit

Journal of Cardiovascular Pharmacology

Volumn 48, Issue 6, 2006, Pages 299-305

  Pakala, Rajbabu ^a   Dilcher, Christian ^a   Baffour, Richard ^a   Hellinga, David ^a   Seabron, Rufus ^a   Joner, Michael ^b   Kolodgie, Frank ^b   Virmani, Renu ^b   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b CVPATH INSTITUTE   (United States)

Author keywords

Atherosclerosis; Neointima; Pioglitazone; Radiation

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BALLOON; CHOLESTEROL DIET; CONTROLLED STUDY; DATA ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFECT; EXPERIMENTAL MODEL; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; MONOCYTE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RADIATION; RECEPTOR AFFINITY; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ACTINS; ADMINISTRATION, ORAL; ANIMALS; BALLOON DILATATION; BODY WEIGHT; CHOLESTEROL, DIETARY; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; RABBITS; THIAZOLIDINEDIONES; TUNICA INTIMA; TUNICA MEDIA;

EID: 33846088365     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000249891.40714.2a     Document Type: Article

References (49)

1. Marx N, Duez H, Fruchart J-C, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
2. Willson T, Brown P, Sternbach D, et al. The PPARs: From orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
3. Chawla A, Repa J, Evans R, et al. Nuclear receptors and lipid physiology: Opening the X-files. Science. 2001;294:1866-1870.
4. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
5. Bardot O, Aldridge TC, Latruffe N, et al. PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun. 1993;192:37-45.
6. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
7. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferatoractivated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
8. Delerive, P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999;274:32048-32054.
9. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998;95:7614-7619.
10. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARγ: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
11. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-793.
12. Sueyoshi S, Yamada T, Niihasi M, et al. Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis. Ann NY Acad Sci. 2001;947:429-432.
13. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000;164:1364-1371.
14. Verges B. Clinical interest of PPARs ligands. Diabetes Metab. 2004;30:7-12.
15. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094-2104.
16. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation. 2000;101:235-238.
17. Han K, Chang MK, Boullier A, et al. Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. J Clin Invest. 2000;106:793-802.
18. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation associated arteriosclerosis. Circ Res. 2002;90:703-710.
19. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
20. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPARgamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-58.
21. Levi Z, Shaish A, Yacov N, et al. Rosiglitazone (PPARγ-agonist) attenuates atherogenesis with no effect on hyperglycemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab. 2003;5:45-50.
22. Li AC, Brown KK, Silvester MJ, et al. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
23. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR∝, β/δ, and γ. J Clin Invest. 2004;114:1564-1576.
24. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-371.
25. Chen, Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001;21:372-377.
26. William P, Barringhaus KG, Sanders JM, et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation. 2003;108:1994-1999.
27. Desouza CV, Murthy SN, Diez J, et al. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats. J Cardiovasc Pharmacol Ther. 2003;8:297-305.
28. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654-26660.
29. Osman A, Otero J, Brizolara A, et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J. 2004;147:e23.
30. Takagi T, Yamamuro A, Tamita K, et al. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. J Cardiol. 2005;45:139-147.
31. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol. 2000;36:1529-1535.
32. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J. 2003;146:E5-E10.
33. Sidhu JS, Kaposzta Z, Markus HS, et al. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930-934.
34. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation. 2005;112:2792-2798.
35. Pakala R, Leborgne L, Cheneau E, et al. Radiation-induced atherosclerotic plaque progression in a hypercholesterolemic rabbit: a prospective vulnerable plaque model? Cardiovasc Radiat Med. 2003;4:146-151.
36. Leborgne L, Pakala R, Dilcher C, et al. Effect of antioxidants on atherosclerotic plaque formation in balloon-denuded and irradiated hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2005;46:540-547.
37. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol. 1994;65:27-33.
38. Tribble DL, Barcellos-Hoff MH, Chu BM, et al. Ionizing radiation accelerates aortic lesion formation in fat-fed mice via SOD inhibitable processes. Arterioscler Thromb Vasc Biol. 1999;19:1387-1392.
39. Hallahan D, Clark ET, Kuchibhotla J, et al. Eselectin gene induction by ionizing radiation is independent of cytokine induction. Biochem Biophys Res Commun. 1995;217:784-795.
40. Quarmby S, Kumar P, Wang J, et al. Irradiation induces up regulation of CD31 in human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:588-597.
41. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866-1874.
42. Galis ZS, Asanuma K, Godin D, et al. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation. 1998;97:2445-2453.
43. Mann JM, Davies MJ. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation. 1996 ;94:928-931.
44. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353 Suppl II:SII5-9.
45. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-1262.
46. Law R, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
47. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001;50:3-11.
48. Tao L, Liu HR, Gao E, et al. Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation. 2003;108:2805-2811.
49. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430-435.